# AllogeneiC Expanded Human MSC Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial

> **NCT05491681** · PHASE1 · WITHDRAWN · sponsor: **BioCardia, Inc.**

## Conditions studied

- ARDS, Human

## Interventions

- **BIOLOGICAL:** intravenous delivery of allogeneic bone marrow-derived MSCs

## Key facts

- **NCT ID:** NCT05491681
- **Lead sponsor:** BioCardia, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2026-01-04
- **Primary completion:** 2026-01-04
- **Final completion:** 2026-01-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** With available funding it was necessary for Sponsor to prioritize other studies. No study participants were consented or enrolled and no study sites were activated.
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05491681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05491681, "AllogeneiC Expanded Human MSC Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05491681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*